Goldman Sachs Group Inc. covered Akorn, Inc. (NASDAQ:AKRX), raising its target price to $20.00 today
- Updated: December 1, 2016
Akorn, Inc. (NASDAQ:AKRX) had its target price raised to $20.00 by Goldman Sachs Group Inc. in a report released Thursday December 01, 2016. The new target price implies a potential downside of -0.06% from the company's most recent stock price close.
Boasting a price of $21.22, Akorn, Inc. (NASDAQ:AKRX) traded -3.55% lower on the day. The last stock close price is down -24.54% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. AKRX has recorded a 50-day average of $24.02 and a 200-day moving average of $28.12. 1,500 shares of AKRX traded hands, down from an average trading volume of 1,385,590
Recent Performance Chart
Akorn, Inc. has 52 week low of $17.57 and a 52 week high of $39.46 with a PE ratio of 14.36 and has a market capitalization of $0.
In addition to Goldman Sachs Group Inc. reporting its stock price target, a total of 11 brokers have issued a research note on the company. The average stock price target is $37.00 with 4 brokers rating the stock a strong buy, 7 brokers rating the stock a buy, 4 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Akorn, Inc. (NASDAQ:AKRX)
Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company's Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.